Page 33 - Accessed May News Today

Phase 3 Maintenance Results Show Patients with Crohns Disease Receiving Risankizumab (SKYRIZI®) Achieved Endoscopic Response and Clinical Remission at One Year - In Crohns disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group)[1] - The overall safet...

Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology -- Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants -- -- Data on the companys investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST -- Horizon Therapeutics plc (N...

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

Zeposia the first and only oral sphingosine 1-phosphate receptor modulator approved for ulcerative colitis 1 represents a new way of treating this chronic immune-mediated disease 2 Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement versus placebo at ...

NOVARTIS AG CHF0.50(REGD) Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints...

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept

/PRNewswire/ -- Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,...

This follow-up report looks at news consumption trends and attitudes a year on from the start of COVID-19.

(0) -- Trial evaluates opportunity to improve outcomes based on emerging data that immunomodulation may offer clinical benefit -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy. For people with chronic gout refractory ...

(BPT) - Arthritis is a common health condition in the United States, affecting one in four adults according to the Centers for Disease Control and Prevention. Characterized by the inflammation